The role of oxidative stress, antioxidants and vascular inflammation in cardiovascular disease (a review)

Vascular Pharmacology

Volumn 71, Issue , 2015, Pages 40-56

  Siti, Hawa N ^a,b   Kamisah, Y ^a   Kamsiah, J ^a  

^a DEPARTMENT OF PHARMACOLOGY   (Malaysia)

^b UNIVERSITI SULTAN ZAINAL ABIDIN   (Malaysia)

Author keywords

Antioxidant; Atherosclerosis; Hypertension; Inflammation; Oxidative stress

Indexed keywords

ALPHA TOCOPHEROL; ANGIOTENSIN II; ANTIOXIDANT; ARACHIDONIC ACID; ASCORBIC ACID; CALCIUM; ENDOTHELIAL NITRIC OXIDE SYNTHASE; ENDOTHELIN 1; INDUCIBLE NITRIC OXIDE SYNTHASE; POLYPHENOL; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; ANTIHYPERTENSIVE AGENT; REACTIVE OXYGEN METABOLITE;

ATHEROSCLEROSIS; BLOOD PRESSURE REGULATION; BLOOD VESSEL TONE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL (TOPIC); DRUG TREATMENT FAILURE; ELEVATED BLOOD PRESSURE; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; ESSENTIAL HYPERTENSION; HUMAN; HYPERLIPIDEMIA; HYPERTENSION; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; OXIDATIVE STRESS; PATHOPHYSIOLOGY; PRESSORECEPTOR REFLEX; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SIGNAL TRANSDUCTION; VASCULITIS; ANIMAL; CARDIOVASCULAR DISEASES; DRUG EFFECTS; INFLAMMATION; METABOLISM; PHYSIOLOGY; RISK FACTOR; VASCULAR ENDOTHELIUM;

ANIMALS; ANTIHYPERTENSIVE AGENTS; ANTIOXIDANTS; ASCORBIC ACID; CARDIOVASCULAR DISEASES; ENDOTHELIUM, VASCULAR; HUMANS; HYPERTENSION; INFLAMMATION; OXIDATIVE STRESS; REACTIVE OXYGEN SPECIES; RISK FACTORS; VITAMIN E;

EID: 84937971920     PISSN: 15371891     EISSN: 18793649     Source Type: Journal    
DOI: 10.1016/j.vph.2015.03.005     Document Type: Review

References (143)

1. Touyz R.M. Molecular and cellular mechanism in vascular injury in hypertension: role of angiotensin II. Curr Opin Nephrol Hypertens 2005, 14(2):125-131. [PMID:15687838, PubMed- indexed for MEDLINE].
2. Griendling K.K., FitzGerald G.A. Oxidative stress and cardiovascular injury part 1: basic mechanisms and in vivo monitoring of ROS. Circulation 2003, 108:1912-1916. 10.1161/01.CIR.0000093660.86242.BB.
3. Mazor R., Itzhaki O., Sela S., Yagil Y., Cohen-Mazor M., Yagil C., et al. Tumor necrosis factor-α: a possible priming agent for the polymorphonuclear leukocyte-reduced nicotinamide-adenine dinucleotide phosphate oxidase in hypertension. Hypertension 2010, 55(2):353-362. 10.1161/HYPERTENSIONAHA.109.144154.
4. Fukutomi M., Hoshide S., Eguchi K., Watanabe T., Kario K. Low-grade inflammation and ambulatory blood pressure response to antihypertensive treatment: the ALPHABET study. Am J Hypertens 2013, 26(6):784-792. 10.1093/ajh/hpt024.
5. Pietri P., Vyssoulis G., Vlachopoulos C., Zervoudaki A., Gialernios T., Konstantinos A., et al. Relationship between low-grade inflammation and arterial stiffness in patients with essential hypertension. J Hypertens 2006, 24(11):2231-2238. 10.1097/01.hjh.0000249701.49854.21.
6. Weiner S.D., Ahmed H.N., Jin Z., Cushman M., Herrington D.M., Nelson J.C., et al. Systemic inflammation and brachial artery endothelial function in the Multi-Ethnic Study of Atherosclerosis (MESA). Heart 2014, 100(11):862-866. 10.1136/heartjnl-2013-304893.
7. Vasilev V., Matrozova J., Elenkova A., Vandeva S., Kirilov G., Zacharieva S. Asymmetric Dimethylarginine (ADMA) and soluble vascular cell adhesion molecule 1 (sVCAM-1) as circulating markers for endothelial dysfunction in patients with pheochromocytoma. Exp Clin Endocrinol Diabetes 2013, 121(09):551-555. 10.1055/s-0033-1353183.
8. Weiss T.W., Arnesen H., Seljeflot I. Components of the interlukin-6 transsignalling system are associated with the metabolic syndrome, endothelial dysfunction and arterial stiffness. Metabolism 2013, 62(7):1008-1013. 10.1016/j.metabol.2013.01.019.
9. Deanfield J.E., Halcox J.P., Rabelink T.J. Endothelial function and dysfunction: testing and clinical relevance. Circulation 2007, 115:1285-1295. [PMID:17353456, PubMed-indexed for MEDLINE].
10. Schiffrin E.L. Oxidative stress, nitric oxide synthase, and superoxide dismutase: a matter of imbalance underlies endothelial dysfunction in the human coronary circulation. Hypertension 2008, 51:31-32. 10.1161/HYPERTENSIONAHA.107.103226.
11. Angela P., Giuseppe D.N., Alberico L.C. LOX-1, ox-LDL and atherosclerosis. Mediat Inflamm 2013, 2013. [Article ID 152786, 12pp.]. 10.1155/2013/152786.
12. Sies H. Oxidative stress: oxidants and antioxidants. Exp Physiol 1997, 82(2):291-295. [PMID:9129943, PubMed - indexed for MEDLINE].
13. Nickening G., Harrison D.G. The AT-1-type angiotensin receptor in oxidative stress and hypertension part I: oxidative stress and atherogenesis. Circulation 2002, 105:393-396. 10.1161/hc0302.102618.
14. Ray R., Shah A.M. NADPH oxidase and endothelial cell function. Clin Sci 2005, 109(3):217-226. [PMID:16104842, PubMed - indexed for MEDLINE].
15. Ebrahimian T., Li M.W., Lemarie C.A., Simeone S.M.C., Pagano P.J., Gaestel M., et al. Mitogen-activated protein kinase-activated protein kinase 2 in angiotensin II-induced inflammation and hypertension: regulation of oxidative stress. Hypertension 2011, 57(2):245-254. 10.1161/HYPERTENSIONAHA.110.159889.
16. Sies H. Total antioxidant capacity: appraisal of a concept. J Nutr 2007, 137(6):1493-1495. [PMID:17513413, PubMed - indexed for MEDLINE].
17. Wang Y., Chun O.K., Song W.O. Plasma and dietary antioxidant status as cardiovascular disease risk factors: a review of human studies. Nutrients 2013, 5(8):2969-3004. 10.3390/nu5082969.
18. Mann G.E., Niehueser-Saran J., Watson A., Gao L., Ishii T., de Winter P., et al. Nrf2/ARE regulated antioxidant gene expression in endothelial and smooth muscle cells in oxidative stress: implications for atherosclerosis and preeclampsia. Acta Phys Sin 2007, 59(2):117-127. [PMID:17437032, PubMed - indexed for MEDLINE].
19. Vaziri N.D. Causal link between oxidative stress, inflammation, and hypertension. Iran J Kidney Dis 2008, 2(1):1-10. [PMID:19367002. PubMed - indexed for MEDLINE].
20. Cai H., Harrison D.G. Endothelial dysfunction in cardiovascular diseases: the role of oxidant stress. Circ Res 2000, 87:840-844. [PMID:11073878, PubMed - indexed for MEDLINE].
21. Majzunova M., Dovinova I., Barancik M., Chan J.Y.H. Redox signaling in pathophysiology of hypertension. J Biomed Sci 2013, 20(1):69. 10.1186/1423-0127-20-69.
22. Ishibashi T. Molecular hydrogen: new antioxidant and anti-inflammatory therapy for rheumatoid arthritis and related diseases. Curr Pharm Des 2013, 19(35):6375-6381. [PMID:23859555, PubMed - indexed for MEDLINE, PMCID:PMC3788323].
23. Ng C.-Y., Yusof K., Othman F., Jaarin K. The role of repeatedly heated soybean oil in the development of hypertension in rats: association with vascular inflammation. Int J Exp Pathol 2012, 93(5):377-387. 10.1111/j.1365-2613.2012.00839.x.
24. Savoia C., Sada L., Zezza L., Pucci L., Lauri F.M., Befani A., et al. Vascular inflammation and endothelial dysfunction in experimental hypertension. Int J Hypertens 2011, 2011:1-8. 10.4061/2011/281240.
25. Pacurari M., Kafoury R., Tchounwou P.B., Ndebele K. The renin-angiotensin-aldosterone system in vascular inflammation and remodeling. Int J Inflamm 2014, 2014:1-13. 10.1155/2014/689360.
26. Horio E., Kadomatsu T., Miyata K., Arai Y., Hosokawa K., Doi Y. Role of endothelial cell-derived angptl2 in vascular inflammation leading to endothelial dysfunction and atherosclerosis progression. Atheroscler Thromb Vasc Biol 2014, 34(4):790-800. 10.1161/ATVBAHA.113.303116.
27. Devaraj S., Kumaresan P.R., Jialal I. C-reactive protein induces release of both endothelial microparticles and circulating endothelial cells in vitro and in vivo: further evidence of endothelial dysfunction. Clin Chem 2011, 57(12):1757-1761. 10.1373/clinchem.2011.169839.
28. Leong X.F., Mohd Najib M.N., Das S., Mustafa M.R., Jaarin K. Intake of repeatedly heated palm oil causes elevation in blood pressure with impaired vasorelaxation in rats. Tohoku J Exp Med 2009, 219:71-78. 10.1186/1476-511X-9-66.
29. Steyers C.M., Miller J.F. Endothelial dysfunction in chronic inflammatory diseases. Int J Mol Sci 2014, 15(7):11324-11349. 10.3390/ijms150711324.
30. Lemkens P., Nelissen J., Meens M.J.P.M.T., Schiffers P.M.H., De Mey J.G.R. Dual neural peptidase/endothelin-converting enzyme inhibition improves endothelial function in mesenteric resistance arteries of young spontaneously hypertensive rats. J Hypertens 2012, 30(9):1799-1808. 10.1097/HJH.0b013e3283569c7a.
31. LaMarca B., Parrish M., Ray L.F., Murphy S.R., Roberts L. Hypertension in response to autoantibodies to the angiotensin II type I receptor (AT1-AA) in pregnant rats: role of endothelin-1. Hypertension 2009, 54(4):905-909. 10.1161/HYPERTENSIONAHA.109.137935.
32. Donato A.J., Gano L.B., Eskurza I., Silver A.E., Gates P.E., Jablonski K., et al. Vascular endothelial dysfunction with aging: endothelin-1 and endothelial nitric oxide synthase. Am J Physiol Heart Circ Physiol 2009, 297(1):H425-H432. 10.1152/ajpheart.00689.2008.
33. Widyantoro B., Emoto N., Nakayama K., Anggrahini D.W., Adiarto S., Iwasa N., et al. Endothelial cell-derived endothelin-1 promotes cardiac fibrosis in diabetis hearts through stimulation of endothelial-to-mesenchymal transition. Circulation 2010, 121(22):2407-2418. 10.1161/CIRCULATIONAHA.110.938217.
34. Barhoumi T., Briet M., Kasal D.A., Paradis P., Schiffrin E.L. Erythropoietin-induced hypertension and vascular injury in mice overexpressing human endothelin-1: exercise attenuated hypertension, oxidative stress, inflammation and immune response. J Hypertens 2014, 32(4):784-794. 10.1097/HJH.0000000000000101.
35. Saleh M.A., Boesen E.I., Pollock J.S., Savin V.J., Pollock D.M. Endothelin-1 increases glomerular permeability and inflammation independent of blood pressure in the rat. Hypertension 2010, 56(5):942-947. 10.1161/HYPERTENSIONAHA.110.156570.
36. Deacon K., Knox A.J. Endothelin-1 (ET-1) increases the expression of remodeling genes in vascular smooth muscle through linked calcium and cAMP pathwyas: role of phospholipase A(2)(sPLA(2))/cyclooxygenase-2 (COX-2)/prostacyclin receptor-dependent autocrine loop. J Biol Chem 2010, 285(34):25913-25927. 10.1074/jbc.M110.139485.
37. Sun X., Kumar S., Sharma S., Aggarwal S., Lu Q. Endothelin-1 induces a glycolytic switch in pulmonary arterial endothelial cells via the mitochondrial translocation of endothelial nitric oxide synthase. Am J Respir Cell Mol Biol 2014, 50(6):1084-1095. 10.1165/rcmb.2013-0187OC.
38. Kuo L., Hein T.W. Vasomotor regulation of coronary microcirculation by oxidative stress: role of arginase. Front Immunol 2013, 4:237. 10.3389/fimmu.2013.00237.
39. Honavar J., Samal A.A., Bradley K.M., Brandon A., Balanay J., Squadrito G.L., et al. Chlorine gas exposure causes systemic endothelial dysfunction by inhibiting endothelial nitric oxide synthase-dependent signaling. Am J Respir Cell Mol Biol 2011, 45(2):419-425. 10.1165/rcmb.2010-0151OC.
40. Weldy Chad S., Wilkerson Hui-wen, Larson Timothy, Stewart James A., Kavanagh T.J. DIESEL particulate exposed macrophages alter endothelial cell expression of eNOS, iNOS, MCP1, and glutathione synthesis genes. Toxicol in Vitro 2011, 25(8):2064-2073. 10.1016/j.tiv.2011.08.008.
41. Zhao X.Q., Zhang M.W., Wang F., Zhao Y.X., Li J.J., Wang X.P., et al. CRP enhances soluble LOX-1 release from macrophages by activating TNF-α converting enzyme. J Lipid Res 2011, 52(5):923-933. 10.1194/jlr.M015156.
42. Forstermann U., Li H. Therapeutic effect of enhancing endothelial nitric oxide synthase (eNOS) expression and preventing eNOS uncoupling. Br J Pharmacol 2011, 164(2):213-223. 10.1111/j.1476-5381.2010.01196.x.
43. Oliveira-Paula G.H., Lacchini R., Tanus-Santos J.E. Inducible nitric oxide synthase as a possible target in hypertension. Curr Drug Targets 2014, 15(2):164-174. [PMID:24102471, PubMed - indexed for MEDLINE].
44. Sankaralingam S., Xu H., Davidge S.T. Arginase contributes to endothelial cell oxidative stress in response to plasma from women with preeclampsia. Cardiovasc Res 2010, 85(1):194-203. 10.1093/cvr/cvp277.
45. Ryoo S., Bhiunia A., Chang F., Shoukas A., Berkowitz D.E., Romer L.H. Ox-LDL-dependent activation of arginase II is dependent on the LOX-1 receptor and downstream RhoA signalling. Atherosclerosis 2011, 214(2):279-287. 10.1016/j.atherosclerosis.2010.10.044.
46. Auclair M., Vigouroux C., Bocoare F., Copd E., Vigeral C., Guerci B., et al. Peroxisome proliferator-activated receptor-γ mutations responsible for lipodystrophy with severe hypertension activate the cellular renin-angiotensin system. Atheroscler Thromb Vasc Biol 2013, 33(4):829-838. 10.1161/ATVBAHA.112.300962.
47. Martin T., Cardarelli P.M., Parry G.C.N., Felts K.A., Cobb R.R. Cytokine induction of monocyte chemoattractant protein-1 gene expression in human endothelial cells depends on the cooperative action of NF-χB and AP-1. Eur J Immunol 1997, 27(5):1091-1097. [PMID:9174597, PubMed - indexed for MEDLINE].
48. Desai A., Darland G., Bland J.S., Tripp M.L., Konda V.R. META060 attenuates TNF-α-activated inflammation, endothelial-monocyte interactions, and matrix metalloproteinase-9 expression, and inhibits NF-κB and AP-1 in THP-1 monocytes. Atherosclerosis 2012, 223(1):130-136. 10.1016/j.atherosclerosis.2012.05.004.
49. Sprague A.H., Khalil R.A. Inflammatory cytokines in vascular dysfunction and vascular disease. Biochem Pharmacol 2009, 78(6):539-552. 10.1016/j.bcp.2009.04.029.
50. Bisaillon J.M., Motiani R.K., Gonzalez-Cobos J.C., Potier M., Halligan K.E., Alzawahra W.F., et al. Essential role for STIM1/Orai 1-mediated calcium influx in PDGF-induced smooth muscle migration. Am J Physiol Cell Physiol 2010, 298(5):C993-C1005. 10.1152/ajpcell.00325.2009.
51. Carnevale D., Vecchione C., Mascio G., Esposito G., Cifelli G., Martinello K., et al. PI3Kγ inhibition reduces blood pressure by a vasorelaxant Akt/L-type calcium channel mechanism. Cardiovasc Res 2012, 93(1):200-209. 10.1093/cvr/cvr288.
52. Sarmiento D., Montorfano I., Cerda O., Caceres M., Becerra A. Increases in reactive oxygen species enhance vascular endothelial cell migration through a mechanism dependent on the transient receptor potential melastatin 4 ion channel. Microvasc Res 2014, 10.1016/j.mvr.2014.02.001.
53. Yeh J.L., Hsu J.H., Liang J.C., Chen I.J., Liou S.F. Lercanidipine and labedipinedilol-A attenuate lipopolysaccharide/interferon-γ-induced inflammation in rat vascular smooth muscle cells through inhibition of HMGB1 release and MMP-2, 9 activities. Atherosclerosis 2013, 226(2):364-372. 10.1016/j.atherosclerosis.2012.12.005.
54. Ledoux J., Werner M.E., Brayden J.E., Nelson M.T. Calcium-activated potassium channels and the regulation of vascular tone. Physiology 2006, 21(1):69-78. 10.1152/physiol.00040.2005.
55. 2+ influx induces chemokine production in monocytes that aggravates inflammatory neutrophil infiltration. Nat Med 2008, 14(7):738-747. 10.1038/nm1758.
56. Schepers E., Glorieux G., Dhondt A., Leybaert L., Vanholder R. Role of symmetric dimethylarginine in vascular damage by increasing ROS via store-operated calcium influx in monocytes. Nephrol Dial Transplant 2009, 24(5):1429-1435. 10.1093/ndt/gfn670.
57. Zhang Q., Raoof M., Chen Y., Sumi Y., Sursal T. Circulating mitochondrial DAMPs cause inflammatory responses to injury. Nature 2010, 464:104-107. 10.1038/nature08780.
58. Li Z., Wang Y., Man R.Y., Vanhoutte P.M. Upregulation of heme oxygenase-1 potentiates EDH-type relaxations in the mesenteric artery of the spontaneously hypertensive rat. Am J Physiol Heart Circ Physiol 2013, 305(10):H1471-H1483. 10.1152/ajpheart.00962.2012.
59. Nagano K., Ishida J., Unno M., Matsukura T., Fukamizu A. Apelin elevates blood pressure in ICR mice with L-NAME-induced endothelial dysfunction. Mol Med Rep 2013, 7(5):1371-1375. 10.3892/mmr.2013.1378.
60. Zhang J., Patel M.B., Griffiths R., Mao A., Song Y.-S., Karlovich N.S., et al. Tumor necrosis factor-α produced in the kidney contributes to Angiotensin-II-dependent hypertension. Hypertension 2014, 64:1275-1281. 10.1161/HYPERTENSIONAHA.114.03863.
61. Tinsley J.H., South S., Chiasson V.L., Mitchell B.M. Interleukin-10 reduces inflammation, endothelial dysfunction, and blood pressure inhypertensive pregnant rats. Am J Physiol Regul Integr Comp Physiol 2010, 298(3):R713-R719. 10.1152/ajpregu.00712.2009.
62. Toma L., Stancu C.S., Sanda G.M., Sima A.V. Anti-oxidant and anti-inflammatory mechanisms of amlodipine action to improve endothelial cell dysfunction induced by irreversibly glycated LDL. Biochem Biophys Res Commun 2011, 411(1):202-207. 10.1016/j.bbrc.2011.06.137.
63. Armoza A., Haim Y., Basiri A., Wolak T., Paran E. Tomato extract and the carotenoids lycopene and lutein improve endothelial function and attenuate inflammatory NF-kB signaling in endothelial cells. J Hypertens 2013, 31(3):521-529. 10.1097/HJH.0b013e32835c1d01.
64. Giles T.D., Sander G.E., Nossaman B.D., Kadowitz P.J. Impaired vasodilation in the pathogenesisn of hypertension: focus on nitric oxide, endothelial-derived hyperpolarizing factors, and prostaglandins. J Clin Hypertens 2012, 14(4):198-205. 10.1111/j.1751-7176.2012.00606.x.
65. Ozkor M.A., Quyyumi A. Endothelium-derived hyperpolarizing factor and vascular function. Cardiol Res Pract 2011, 1(1):156146. 10.4061/2011/156146.
66. Renna N.F., Lembo C., Diez E., Miatello R.M. Role of renin-angiotensin system and oxidative stress on vascular inflammation in insulin resistence model. Int J Hypertens 2013, 2013:1-9. [Article ID 420979, 9pp.]. 10.1155/2013/420979.
67. Hayenga H.N., Aranda-Espinoza H. Stiffness increases mononuclear cell transendothelial migration. Cell Mol Bioeng 2013, 6(3):253-265. 10.1007/s12195-013-0284-9.
68. Van Bussel B.C.T., Henry R.M.A., Schalkwijk C.G., Dekker J.M., Nijpels G., Stehouwer C.D.A. Low-grade inflammation, but not endothelial dysfunction, is associated with greater carotid stiffness in the elderly: the Hoorn study. J Hypertens 2012, 30(4):744-752. 10.1097/HJH.0b013e328350a487.
69. Gkaliagkousi E., Doumas M., Gavriilaki E., Vogiatzis K., Anyfanti P., Petidis K., et al. Elevated levels of MMP-9 in untreated patients with stage I essential hypertension. Clin Exp Hypertens 2012, 34(8):561-566. 10.3109/10641963.2012.681726.
70. Goyal T., Mitra S., Khaidakov M., Khaidakov M., Wang X., Singla S., et al. Current concepts of the role of oxidized LDL receptors in atherosclerosis. Curr Atheroscler Rep 2012, 14(2):150-159.
71. Pirillo A., Norata G.D., Catapano A.L. LOX-1, ox-LDL, and atherosclerosis. Mediat Inflamm 2013, 2013:152786. 10.1155/2013/152786.
72. Stein S., Lohmann C., Schafer N., Hofmann J., Rohrer L., Besler C., et al. SIRT1 decreases LOX-1-mediated foam cell formation in atherogenesis. Eur Heart J 2010, 31:2301-2309. 10.1093/eurheartj/ehq107.
73. Chen X., Zhang H., McAfee S., Zhang C. The reciprocal relationship between adiponectin and LOX-1 in the regulation of endothelial dysfunction in ApoE knockout mice. Am J Physiol Heart Circ Physiol 2010, 299(3):H605-H612. 10.1152/ajpheart.01096.2009.
74. Zhou M.S., Tian R., Jaimes E.A., Raij L. Combination therapy of amlodipine and atorvastatin has more beneficial vascular effects than monotherapy in slat-sensitive hypertension. Am J Hypertens 2014, 27(6):873-880. 10.1093/ajh/hpt272.
75. Lubrano V., Balzan S. LOX-1 and ROS, inseparable factors in the process of endothelial damage. Free Radic Res 2014, 48(8):841-848. 10.3109/10715762.2014.929122.
76. Zhou J., Abid M.D.N., Xiong Y., Chen Q., Chen J. Ox-LDL downregulates eNOS activity via LOX-1-mediated endoplasmic reticulum stress. Int J Mol Med 2013, 32(6):1442-1450. 10.3892/ijmm.2013.1513.
77. Adam S.K., Soelaiman I.N., Umar N.A., Mokhtar N., Mohamed N., Jaarin K. Effects of repeatedly heated palm oil on serum lipid profile, lipid peroxidation and homocystein levels in a post-menopausal rat model. McGill J Med 2008, 11(2):145-151. [PMCID: PMC2582674].
78. Kenney W.L., Cannon J.G., Alexander L.M. Cutaneous microvascular dysfunction correlates with serum LDL and sLOX-1 receptor concentrations. Microvasc Res 2012, 85(1):112-117. 10.1016/j.mvr.2012.10.010.
79. Ozyazgan S., Uzun H., Tuzcu O.B., Ugurlu S., Andian G. Lectin-like oxidised LDL receptor-1 as a marker of endothelial dysfunction in Bechet's disease. Clin Exp Rheumatol 2013, 31(77):71-76. [PMID:24064019, PubMed - indexed for MEDLINE].
80. Goncalves I., Edsfeldt A., Ko N.Y., Grufman H., Berg K., Bjorkbacka H., et al. Evidence supporting a key role of Lp-PLA2-generated lypophosphatidylcholine in human atherosclerotic plaque inflammation. Atheroscler Thromb Vasc Biol 2012, 32(6):1505-1512. 10.1161/ATVBAHA.112.249854.
81. Racherla S., Arora R. Utility of Lp-PLA2 in lipid-lowering therapy. Am J Ther 2012, 19(2):115-120. 10.1097/MJT.0b013e3181e70d32.
82. Borsch-Haubold A.G., Pasquet S., Watson S.P. Direct inhibition of cyclooxygenase -1 and -2 by the kinase inhibitors SB 203580 and PD 98059 SB 203580 also inhibits thromboxane synthase. J Biol Chem 1998, 273(44):28766-28772. [PMID:9786874, PubMed - indexed for MEDLINE].
83. Dileep K.V., Tintu I., Mandal P.K., Karthe P., Haridas M., Sadasivan C. Binding to PLA2 may contribute to the anti-inflammatory activity of cathecol. Chem Biol Drug Des 2012, 79(1):143-147. 10.1111/j.1747-0285.2011.01258.x.
84. Mendes R.T., Stanczyk C.P., Sordi R., Otuki M.F., Dos Santos F.A., Fernandes D. Selective inhibition of cyclooxygenase-2: risks and benefits. Rev Bras Reumatol 2012, 52(5):767-782. [PMID:23090376, PubMed - indexed for MEDLINE].
85. Toniolo A., Buccellati C., Pinna C., Gaion R.M., Sala A., Bolego C. Cyclooxygenase-1 and prostacyclin production by endothelial cells in the presence of mild oxidative stress. PLoS ONE 2013, 8(2):e56683. 10.1371/journal.pone.0056683.
86. Kirby N.S., Lundberg M.H., Harrington L.S., Leadbeater P.D.M., Milne G.L., Potter C.M. Cyclooxygenase-1, not cyclooxygenase-2, is responsible for physiological productionof prostacyclin in the cardiovascular system. PNAS 2012, 109(43):17597-17602. 10.1073/pnas.1209192109.
87. Davi G., Patrono C. Mechanisms of disease: platelet activation and atherothrombosis. N Engl J Med 2007, 357(24):2482-2494. 10.1056/NEJMra071014.
88. Buie J.N.J., Oates J.C. Role of interferon alpha in endothelial dysfunction: insights into endothelial nitric oxide synthase-related mechanisms. Am J Med Sci 2014, 348(2):168-175. 10.1097/MAJ.0000000000000284.
89. Sedeek M., Hebert R.L., Kennedy C.R., Burns K.D., Touyz R.M. Molecular mechanisms of hypertension: role of Nox family NADPH oxidases. Curr Opin Nephrol Hypertens 2009, 18(2):122-127. 10.1097/MNH.0b013e32832923c3.
90. Munzel T.A., Gori T.A., Bruno R.M.B., Taddei S.B. Is oxidative stress a therapeutic target in cardiovascular disease?. Eur Heart J 2010, 31(22):2741-2749. 10.1093/eurheartj/ehq396.
91. Jasinska M., Owczareck J., Orszulak-Michalak D. Statins: a new insight into teir mechanisms of action and consequent pleiotropic effects. Pharmacol Rep 2007, 59:483-499. [PMID:18048949, PubMed - indexed for MEDLINE].
92. Taguchi I., Toyoda S., Takano K., Arikawa T., Kikuchi M., Ogawa M., et al. Irbesartan, an angiotensin receptor blocker, exhibit metabolic, anti-inflammatory and antioxidative effects in patients with high-risk hypertension. Hypertens Res 2013, 36(7):608-613. 10.1038/hr.2013.3.
93. Halliwell B., Gutteridge J.M.C. Antioxidant defences: endogenous and diet derived in FreeRadicals in Biology and Medicine 2007, Oxford University Press, Clarendon. 4th ed.
94. Litescu S.C., Eremia S., Radu G.L. Methods for determination of antioxidant capacity in food and raw materials. Advances in Experimental Medicine and Biology 2010, 698(18):241-249. Springer, US.
95. Flores-Mateo G., Navas-Acien A., Pastor-Barriuso R., Guallar E. Selenium and coronary heart disease: a meta-analysis. Am J Clin Nutr 2006, 84(4):762-773. [PMID:17023702, PubMed - indexed for MEDLINE].
96. Nishi E.E., Campos R.R., Bergamaschi C.T., de Almeida V.R., Ribeiro D.A. Vitamin C prevents DNA damage induced by renovascular hypertension in multiple organs of Wistar rats. Hum Exp Toxicol 2010, 29(7):593-599. 10.1177/0960327109358267.
97. Botelho-Ono M.S., Pina H.V., Sousa K.H.F., Nunes F.C., Medeiros I.A., Braga V.A. Acute superoxide scavenging restores depressed baroreflex sensitivity in renovascular hypertensive rats. Auton Neurosci 2011, 159(1-2):38-44. 10.1016/j.autneu.2010.07.025.
98. Bruno R.M., Daghini E., Ghiadoni L., Sudano I., Rugani I., Varanini M., et al. Effect of acute administration of vitamin C on muscle sympathetic activity, cardiac sympathovagal balance, and baroreflex sensitivity in hypertensive patients. Am J Clin Nutr 2012, 96(2):302-308. 10.3945/ajcn.112.035022.
99. Albaghdadi M. Baroreflex control of long-term arterial pressure. Rev Bras Hipertens 2007, 14(4):212-225.
100. Yamazaki F. Oral vitamin C enhances the adrenergic vasoconstrictor response to local cooling in human skin. J Appl Physiol 2012, 112(10):1689-1697. 10.1152/japplphysiol.00043.2012.
101. Esmaeilpour-Bezenjani K., Abbasnejad M. Effect of administration of ascorbic acid and dopamine D2 receptors agonist in the hippocampal CA1 area on spatial learning and memory in adult male rats. Iran J Vet Res 2013, 14(2):126-132.
102. Chelazzi C., Villa G., De Gaudio A.R. Postoperative Atrial Fibrillation. International Scholarly Research Network (ISRN) Cardiology 2011, 2011. [Article ID 203179, 10pp.]. 10.5402/2011/203179.
103. Uzun A., Yener U., Cicek O.F., Yener O., Yalcinkaya A., Diken A., et al. Does vitamin C or its combination with vitamin e improve radial artery endothelium-dependent vasodilatation in patients awaiting coronary artery bypass surgery?. Cardiovasc J Afr 2013, 24(7):255-259. 10.5830/CVJA-2013-046.
104. May J.M., Harrison F.E. Role of vitamin C in the function of the vascular endothelium. Antioxid Redox Signal 2013, 19(17):2068-2083. 10.1089/ars.2013.5205.
105. Carr A.C., Vissers M.C.M. Synthetic or food-derived vitamin C-Are they equally bioavailable?. Nutrients 2013, 5(11):4284-4304. 10.3390/nu5114284.
106. Agarwal M., Mehta P.K., Dwyer J.H., Dwyer K.M., Shircore A.M., Nordstrom C.K., et al. Differing relations to early atherosclerosis between vitamin C from supplements vs. food in the Los Angeles atherosclerosis study: a prospective cohort study. Open Cardiovasc Med J 2012, 6:113-121. [PMID:23002405, PubMed, PMCID:PMC3447163].
107. Loke W.M., Proudfoot J.M., Hodgson J.M., Stocker R., Croft K.D. Specific dietary polyphenols attenuate atherosclerosis in apolipoprotein e-knockout mice by alleviating inflammation and endothelial dysfunction. Atheroscler Thromb Vasc Biol 2010, 30(4):749-757. 10.1161/ATVBAHA.109.199687.
108. Scoditti E., Calabriso N., Massaro M., Pellegrino M., Storelli C., Martines G., et al. Mediterranean diet polyphenols reduce inflammatory angiogenesis through MMP-9 and COX-2 inhibition in human vascular endothelial cells: a potentially protective mechanism in atherosclerotic vascular disease and cancer. Arch Biochem Biophys 2012, 527(2):81-89. 10.1016/j.abb.2012.05.003.
109. Mukai Y., Sato S. Polyphenol-containing azuki bean (Vigna angularis) seed coats attenuate vascular oxidative stress and inflammation in spontaneously hypertensive rats. J Nutr Biochem 2011, 22(1):16-21. 10.1016/j.jnutbio.2009.11.004.
110. Natsume M., Baba S. Suppressive effects of cacao polyphenols on the development of atherosclerosis in apolipoprotein E-deficient mice. Subcell Biochem 2014, 77:189-198. 10.1007/978-94-007-7920-4_16.
111. Cuevas A., Saavedra N., Cavalcante M.F., Salazar L.A., Abdalla D.S.P. Identification of microRNAs involved in the modulation of pro-angiogenic factors in atherosclerosis by a polyphenol-rich extract from propolis. Arch Biochem Biophys 2014, 557:28-35. 10.1016/j.abb.2014.04.009.
112. Widmer R.J., Freund M.A., Flammer A.J., Sexton J., Lennon R., Romani A., et al. Beneficial effects of polyphenol-rich olive oil in patients with early atherosclerosis. Eur J Nutr 2013, 52(3):1223-1231. 10.1007/s00394-012-0433-2.
113. Botden I.P.G., Draijer R., Westerhof B.E., Rutten J.H., Langendonk J.G., Sijbrands E.J., et al. Red wine polyphenols do not lower peripheral or central blood pressure in high normal blood pressure and hypertension. Am J Hypertens 2012, 25(6):718-723. 10.1038/ajh.2012.25.
114. Ras R.T., Zock P.L., Zebregs Y.E., Johnston N.R., Webb D.J., Draijer R. Effect of polyphenol-rich grape seed extract on ambulatory blood pressure in subjects with pre- and stage I hypertension. Br J Nutr 2013, 110(12):2234-2241. 10.1017/S000711451300161X.
115. Da Costa C.A., de Oliveira P.R., de Bem G.F., de Cavalho L.C., Ognibene D.T., da Silva A.F., et al. Euterpe oleracea Mart-derived polyphenols prevent endothelial dysfunction and vascular structural changes in renovascular hypertensive rats: role of oxidative stress. Naunyn Schmiedeberg's Arch Pharmacol 2012, 385(12):1199-1209. 10.1007/s00210-012-0798-z.
116. Hou S.-Z., Xu S.-J., Jiang D.X., Chen S.X., Wang L.L., Huang S., et al. Effect of the flavonoid fraction of Lithocarpus polystachyus Rehd on spontaneously hypertensive and normotensive rats. J Ethnopharmacol 2012, 143(2):441-447. 10.1016/j.jep.2012.06.016.
117. Li Z., Wang C.-Y., Zhang S.-P., Wang J.-L., Zhang X.-M., He Q.-Q. Effect of total flavonoids in Apocynum venetum leaves on rat hypertension induced by high fat and high salt and its molecular mechanism. Chin Tradit Herb Drugs 2012, 43(3):540-545.
118. Harari A., Abecassis R., Relevi N., Harats D., Shaish A. Prevention of atherosclerosis progression by 9-cis-β-carotene rich alga dunaliella in apoE-deficient mice. Biomed Res Int 2013, 2013:169517. 10.1155/2013/169517.
119. Meydani M., Kwan P., Band M., Goutis J., Ordovas J. Long-term vitamin E supplementation reduces atherosclerosis and mortality in Ldlr-/- mice, but not when fed Western style diet. Atherosclerosis 2014, 233(1):196-205. 10.1016/j.atherosclerosis.2013.12.006.
120. Boni A., Pugliese C., Claudio C.C., Patin R.V., Oliveira F.L.C. Antioxidant vitamins and prevention of atherosclerosis in childhood. Rev Paul Pediatr 2010, 28(4):373-380. 10.1590/S0103-05822010000400014.
121. Bozaykut P., Karademir B., Yazgan B., Sozen E., Siow R.C., Mann G.E., et al. Effects of vitamin E on peroxisome proliferator-activated receptor γ and nuclear factor-erythroid 2-related factor 2 in hypercholesterolemia-induced atherosclerosis. Free Radic Biol Med 2014, 70:174-181. 10.1016/j.freeradbiomed.2014.02.017.
122. Che Idris C.A., Karupaiah T., Sundram K., Tan Y.A., Balasundram N., Nasruddin N.S., et al. Oil palm phenolics and vitamin E reduce atherosclerosis in rabbits. J Funct Foods 2014, 7(1):541-550. 10.1016/j.jff.2014.01.002.
123. Rasool A.H.G., Yuen K.H., Yusoff K., Wong A.R., Rahman A.R.A. Dose dependent elevation of plasma tocotrienol levels and its effect on arterial compliance, plasma total antioxidant status, and lipid profile in healthy humans supplemented with tocotrienol rich vitamin E. J Nutr Sci Vitaminol 2006, 52(6):473-478. [PMID:17330512, PubMed - indexed for MEDLINE].
124. Young I.S. Measurement of total antioxidant capacity. J Clin Pathol 2001, 54(5):339. 10.1136/jcp.54.5.339.
125. Weydert C.J., Cullen J.J. Measurement of superoxide dismutase, catalase and glutathione peroxidase in cultured cells and tissue. Nat Protoc 2010, 5(1):51-66. 10.1038/nprot.2009.197.
126. Mahajan A.S., Babbar R., Kansal N., Agarwal S.K., Ray P.C. Antihypertensive and antioxidant action of amlodipine and vitamin C in patients of essential hypertension. J Clin Biochem Nutr 2007, 40(2):141-147. 10.3164/jcbn.40.141.
127. Rodrigo R., Prat H., Passalacqua W., Araya J., Bächler J.P. Decrease in oxidative stress through supplementation of vitamins C and E is associated with a reduction in blood pressure in patients with essential hypertension. Clin Sci 2008, 114(9-10):625-634. [PMID:17999638, PubMed - indexed for MEDLINE].
128. Plantinga Y., Ghiadoni L., Magagna A., Giannarelli C., Franzoni F., Taddei S., et al. Supplementation with vitamins C and E improves arterial stiffness and endothelial function in essential hypertensive patients. Am J Hypertens 2007, 20(4):392-397. [PMID:17386345, PubMed - indexed for MEDLINE].
129. Milman U., Blum S., Shapira C., Aronson D., Miller-Lotan R., Anbinder Y., et al. Vitamin E supplementation reduces cardiovascular events in a subgroup of middle-aged individuals with both type 2 diabetes mellitus and the haptoglobin 2-2 genotype: a prospective double-blinded clinical trial. Arterioscler Thromb Vasc Biol 2008, 28(2):341-347. [PMID:18032779, PubMed - indexed for MEDLINE].
130. Shargorodsky M., Debby O., Matas Z., Zimlichman R. Effect of long-term treatment with antioxidants(vitamin C, vitamin E, coenzyme Q10 and selenium)on arterial compliance, humoral factors and inflammatory markers in patients with multiple cardiovascular risk factors. Nutr Metab 2010, 7:55. 10.1186/1743-7075-7-55.
131. Hawkes W.Y., Laslett L.J. Selenium supplementation does not improve vascular responsiveness in healthy North American men. Am J Physiol Heart Circ Physiol 2009, 296(2):H256-H262. 10.1152/ajpheart.00935.2008.
132. Edwards R.L., Lyon T., Litwin S.E., Rabovsky A., Symons J.D., Jalili T. Quercetin reduces blood pressure in hypertensive subjects. J Nutr 2007, 137(11):2405-2411.
133. Cook N.R., Albert S.M., Gaziano J.M., Zaharris E., MacFadyen J., Danielson E., et al. A randomized factorial trial of vitamins c, e, and beta-carotene in the secondary prevention of cardiovascular events in women: results from the Women's Antioxidant Cardiovascular Study (WACS). Arch Intern Med 2007, 167(15):1610-1618. 10.1001/1rchinte.167.15.1610.
134. Sesso H.D., Buring J.E., Christen W.G., Kurth T., Belanger C., MacFadyen J., et al. Vitamins E and C in the prevention of cardiovascular disease in men: the Physicians' Health Study II randomized trial. JAMA 2008, 300(18):2123-2133. 10.1001/jama.2008.600.
135. Belch J., MacCuish A., Campbell I., Cobbe S., Taylor Roy, Prescott R., et al. The prevention of progression of arterial disease and diabetes (POPADAD) trial: factorial randomised placebo controlled trial of aspirin and antioxidants in patients with diabetes and asymptomatic peripheral arterial disease. BMJ 2008, 337:a1840. 10.1136/bmj.a1840.
136. Kidd P.M. Bioavailability and activity of phytosome complexes from botanical polyphenols: the silymarin, curcumin, green tea, and grape seed extract. Altern Med Rev 2009, 14(3):226-246. [PMID:19803548, PubMed - indexed for MEDLINE].
137. McCullough M.L., Peterson J.J., Patel R., Jacques P.F., Shah R., Dwyer J.T. Flavonoid intake and cardiovascular disease mortality in a prospective cohort of US adults. Am J Clin Nutr 2012, 95(2):454-464. 10.3945ajcn.111.016634.
138. Mink P.J., Scrafford C.G., Barraj L.M., Harnack L., Harnack L., Hong C.-P., et al. Flavonoid intake and cardiovascular disease mortality: a prospective study in postmenopausal women. Am J Clin Nutr 2007, 85(3):895-909.
139. Mursu J., Voutilainen S., Nurmi T., Tuomainen T.P., Kurl S., Salonen J.T. Flavonoid intake and the risk of ischaemic stroke and CVD mortality in middle-aged Finnish men: the Kuopio Ischaemic Heart Disease Risk Factor Study. Br J Nutr 2008, 100(4):890-895. 10.1017/S0007114508945694.
140. Lin J., Rexrode K.M., Hu F., Albert C.M., Chae C.U., Rimm E.B., et al. Dietary intakes of flavonols and flavones and coronary heart disease in US women. Am J Epidemiol 2007, 165(11):1305-1313. 10.1093/aje/kwm016.
141. Buijsse B., Feskens E.J.M., Kwape L., Kok F.J., Kromhout D. Both a- and b carotene, but not tocopherols and vitamin C, are inversely related to 15-year cardiovascular mortality in Dutch elderly men. J Nutr 2008, 138(2):344-350. [PMID:18203902, PubMed - indexed for MEDLINE].
142. Del Rio D., Agnoli C., Pellegrini N., Krogh V., Brighenti F., Mazzeo T., et al. Total antioxidant capacity of the diet is associated with lower risk of ischemic stroke in a large Italian cohort. J Nutr 2011, 141(1):118-123. 10.3945/jn.110.125120.
143. Rautiainen S., Larsson S., Virtamo J., Wolk A. Total antioxidant capacity of diet and risk of stroke: a population-based prospective cohort of women. Stroke 2012, 43:335-340. 10.1161/STROKEAHA.111.635557.